Immunic, Inc. (IMUX): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of IMUX were reported in the last 12 months. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who owns IMUX
55 funds and institutions reported IMUX shares worth $134M at the end of Q2 2026, about 6% of the company. The largest holder is Aberdeen Group plc with 0.6%.
Funds and institutions (13F) 6%Everyone else 94%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Aberdeen Group plc | 824,393 | 0.61% | $12.7M | – |
| Bvf Inc | 765,295 | 0.56% | $11.8M | – |
| Millennium Management LLC | 740,347 | 0.54% | $11.4M | – |
| Avidity Partners Management LP | 669,941 | 0.49% | $10.3M | – |
| Braidwell LP | 645,010 | 0.47% | $9.9M | – |
| Laurion Capital Management LP | 610,326 | 0.45% | $9.4M | – |
| Vanguard Capital Management LLC | 571,561 | 0.42% | $8.8M | – |
| Jones Hill Capital LP | 539,814 | 0.40% | $8.3M | – |
| Nantahala Capital Management, LLC | 501,292 | 0.37% | $7.7M | – |
| Woodline Partners LP | 471,528 | 0.35% | $7.2M | – |
| Soleus Capital Management, L.P. | 450,000 | 0.33% | $6.9M | – |
| Propel Bio Management, LLC | 325,022 | 0.24% | $5M | – |
| UBS Group AG | 175,756 | 0.13% | $2.7M | – |
| Geode Capital Management, LLC | 170,675 | 0.13% | $2.6M | – |
| 683 Capital Management, LLC | 147,245 | 0.11% | $2.3M | – |
| Adage Capital Partners Gp, L.l.c. | 139,860 | 0.10% | $2.1M | – |
| BlackRock, Inc. | 132,791 | 0.10% | $2M | – |
| Marshall Wace, LLP | 104,816 | 0.08% | $1.6M | – |
| Susquehanna International Group, LLP | 90,890 | 0.07% | $1.4M | – |
| Jane Street Group, LLC | 89,687 | 0.07% | $1.4M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No IMUX insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
IMUX short interest
High short interest. 14.3% of IMUX shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 25%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.95M IMUX shares were sold short, 14.3% of the shares outstanding, up 4.8% from the report before. At the average daily volume of 340,571 shares, buying them all back would take about 5.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.95M | 14.29% | +5% | 340,571 | 5.7 |
| Oct 15, 2026 | 1.86M | 13.64% | -10% | 454,131 | 4.1 |
| Sep 30, 2026 | 2.08M | 15.21% | +16% | 455,370 | 4.6 |
| Sep 15, 2026 | 1.79M | 13.15% | +20% | 356,386 | 5.0 |
| Aug 31, 2026 | 1.49M | 10.93% | +17% | 194,796 | 7.7 |
| Aug 14, 2026 | 1.28M | 9.36% | -11% | 182,161 | 7.0 |
| Jul 31, 2026 | 1.43M | 10.51% | +1% | 141,495 | 10.1 |
| Jul 15, 2026 | 1.41M | 1.04% | -11% | 149,504 | 9.5 |
| Jun 30, 2026 | 1.59M | 1.17% | -3% | 211,003 | 7.5 |
| Jun 15, 2026 | 1.63M | 1.20% | -8% | 223,425 | 7.3 |
| May 29, 2026 | 1.76M | 1.30% | +13% | 266,625 | 6.6 |
| May 15, 2026 | 1.57M | 1.15% | +17% | 273,036 | 5.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Immunic company events
Immunic filed 21 reports on Form 8-K in the last 12 months, 12 of them about an important change (leadership, listing). The latest was on Nov 5, 2026.
- Nov 5, 2026AnnouncementShared information with investors. Filing
- Sep 11, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
- Sep 9, 2026AnnouncementShared information with investors. Filing
- Aug 11, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
- Jul 14, 2026AnnouncementShared information with investors. Filing
- Jul 6, 2026LeadershipTamar Howson resigned as a member of the Compensation Committee of the Board of Directors of Immunic, Inc., a Delaware corporation, and as a member of the Board, as Ms. Howson transitions into retirement. Filing
- Jun 29, 2026LeadershipImmunic, Inc., a Delaware corporation held its annual meeting of stockholders . At the Meeting, the Company’s stockholders approved an amendment to the Company’s 2019 Omnibus Equity Incentive Plan, as amended, to increase the number of shares of common stock, par value $0.0001 per share, authorized… Filing
- May 28, 2026AnnouncementShared information with investors. Filing
- May 27, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
- May 19, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
- May 13, 2026ResultsReleased financial results. Filing
- Apr 28, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
- Apr 23, 2026AnnouncementThe Company issued a press release to announce the effective date for the Reverse Stock Split. Filing
- Apr 14, 2026AnnouncementIn connection with the result of the Special Meeting, the Board approved a reverse stock split of the Company’s issued and outstanding Common Stock, at a ratio of 1-for-10 shares, expected to effective at 12:01 a.m. Filing
- Apr 10, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
- Apr 1, 2026AnnouncementImmunic, Inc. received a written notification from The Nasdaq Stock Market LLC notifying the Company that Nasdaq has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) by maintaining a minimum closing bid price of the Company’s common stock, par value $0.0001… Filing
- Mar 31, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Feb 13, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
- Jan 6, 2026ListingImmunic, Inc. received approval from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC that the Company’s application to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market has been approved. Filing
- Jan 5, 2026LeadershipDeparture of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Immunic financials
Famous investors that hold IMUX
4 of the 50 well-known investors we track reported holding IMUX in their latest 13F filing. The largest position is Israel Englander's, worth $6.3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 681,024 | $6.3M | 0.0% | -8% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 129,654 | $1.2M | 0.0% | +500% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 71,330 | $663K | 0.0% | New |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 10,806 | $100K | 0.0% | No change |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named IMUX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | OrbiMed Advisors LLC | 13G/A | 2.3% |
| Nov 16, 2026 | Integrated Core Strategies (US) LLC | 13G/A | 4.3% |
| Nov 16, 2026 | Integrated Core Strategies (US) LLC | 13G/A | 4.3% |
| Nov 16, 2026 | OrbiMed Advisors LLC | 13G/A | 2.3% |
| Nov 13, 2026 | Morgan Stanley | 13G | 5.2% |
| Nov 13, 2026 | Morgan Stanley | 13G | 5.2% |
| Nov 2, 2026 | Aberdeen Group plc | 13G/A | 8.0% |
| Nov 2, 2026 | Aberdeen Group plc | 13G/A | 8.0% |
Questions about Immunic, Inc. (IMUX) stock
Who owns the most IMUX stock?
The largest reported owner of Immunic, Inc. (IMUX) is Aberdeen Group plc, with 0.6% of the company. In total, 55 funds and institutions reported holding IMUX at the end of Q2 2026, together about 6% of the shares. See the largest owners.
Are IMUX insiders buying or selling?
No IMUX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in IMUX?
As of Oct 30, 2026, 1.95M IMUX shares were sold short, 14.3% of the shares outstanding, up 4.8% from the report before. At the average daily volume of 340,571 shares, buying them all back would take about 5.7 trading days (days to cover). See the history.
Which famous investors hold IMUX?
4 of the 50 well-known investors we track reported IMUX in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $6.3M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.